1.
Beatrice Drexler, Jakob R. Passweg, Alexandar Tzankov, Martin Bigler, Alexandre PA Theocharides, Nathan Cantoni, Peter Keller, Georg Stussi, Axel Ruefer, Rudolf Benz, Geneviève Favre, Pontus Lundberg, Ronny Nienhold, Andrea Fuhrer, Christine Biaggi, Markus G. Manz, Mario Bargetzi, Simon Mendez-Ferrer, Radek C. Skoda. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica 2019;104(4):710-716; https://doi.org/10.3324/haematol.2018.200014.